Pharma Deals Review, Vol 2002, No 31 (2002)

Font Size:  Small  Medium  Large

Allergan Licenses Phase I Skin Cancer Drug from Peplin

Business Review Editor

Abstract


Allergan acquired the rights to PEP 005 product useful for treating nonmelanoma skin cancer and actinic keratosis from Peplin Biotech. Allergan also acquired the rights to develop and commercialize the drug in North and South America. The deal could be worth up to US$23 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.